Michaely Peter, Zhao Zhenze, Li Wei-Ping, Garuti Rita, Huang Lily J, Hobbs Helen H, Cohen Jonathan C
Department of Cell Biology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
EMBO J. 2007 Jul 25;26(14):3273-82. doi: 10.1038/sj.emboj.7601769. Epub 2007 Jun 21.
The low-density lipoprotein (LDL) receptor (LDLR) binds to and internalizes lipoproteins that contain apolipoproteinB100 (apoB100) or apolipoproteinE (apoE). Internalization of the apoB100 lipoprotein ligand, LDL, requires the FDNPVY(807) sequence on the LDLR cytoplasmic domain, which binds to the endocytic machinery of coated pits. We show here that inactivation of the FDNPVY(807) sequence by mutation of Y807 to cysteine prevented the uptake of LDL; however, this mutation did not prevent LDLR-dependent uptake of the apoE lipoprotein ligand, beta-VLDL. Comparison of the surface localization of the LDLR-Y807C using LDLR-immunogold, LDL-gold and beta-VLDL-gold probes revealed enrichment of LDLR-Y807C-bound beta-VLDL in coated pits, suggesting that beta-VLDL binding promoted the internalization of the LDLR-Y807C. Consistent with this possibility, treatment with monensin, which traps internalized LDLR in endosomes, resulted in the loss of surface LDLR-Y807C only when beta-VLDL was present. Reconstitution experiments in which LDLR variants were introduced into LDLR-deficient cells showed that the HIC(818) sequence is involved in beta-VLDL uptake by the LDLR-Y807C. Together, these experiments demonstrate that the LDLR has a very low-density lipoprotein (VLDL)-induced, FDNPVY-independent internalization mechanism.
低密度脂蛋白(LDL)受体(LDLR)可结合并内化含有载脂蛋白B100(apoB100)或载脂蛋白E(apoE)的脂蛋白。apoB100脂蛋白配体LDL的内化需要LDLR细胞质结构域上的FDNPVY(807)序列,该序列与被膜小窝的内吞机制结合。我们在此表明,通过将Y807突变为半胱氨酸使FDNPVY(807)序列失活可阻止LDL的摄取;然而,这种突变并未阻止LDLR依赖性的apoE脂蛋白配体β-VLDL的摄取。使用LDLR免疫金、LDL金和β-VLDL金探针比较LDLR-Y807C的表面定位,发现被膜小窝中LDLR-Y807C结合的β-VLDL富集,这表明β-VLDL结合促进了LDLR-Y807C的内化。与此可能性一致的是,用莫能菌素处理可将内化的LDLR捕获在内体中,仅当存在β-VLDL时才会导致表面LDLR-Y807C的丢失。将LDLR变体引入LDLR缺陷细胞的重组实验表明,HIC(818)序列参与了LDLR-Y807C对β-VLDL的摄取。总之,这些实验证明LDLR具有极低密度脂蛋白(VLDL)诱导的、不依赖FDNPVY的内化机制。